Prostate Cancer Blog - malecare.org

New Research Contradicts Prior Understanding – Intermittent Hormone Therapy for Prostate Cancer Inferior to Continuous Therapy

At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]

By Malecare|2017-10-19T10:51:07-04:00June 4th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|1 Comment

From ASCO: Enzalutamide (MDV-3100) Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event

The American Society of Clinical Oncologists (ASCO) has started their annual conference in Chicago. I am anticipating a number of interesting and important abstracts that will be directly relevant to those of us with advanced prostate cancer. Among the first release of information comes an announcement from Medivation Inc. and Astellas Pharma Inc. who have [...]

By Malecare|2012-06-02T12:08:12-04:00June 2nd, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), MDV3100, On The Horizon, Uncategorized|0 Comments

FOR OUR 6th BIRTHDAY WE MOVED!

Six years ago in this month I started the fatherdad.com/African American Dad blog through Malecare Inc. Since then I have been writing and working on a so many projects in addition to my regular 9-5 work that I am kind of dizzy. Even when I have gone radio silent for long stretches, I'm usually busy [...]

By Malecare|2022-08-25T16:54:51-04:00May 31st, 2012|Black Dad Connection|0 Comments

Important Additional Information About Early/Expanded Access to Enzalutamide (MDV-3100)

I now have some additional information about the Early/Expanded Access Program for Enzalutamide (MDV-3100)for men with advanced prostate cancer. Jan Manarite, who is a member of the Early Access Committee has provided the following information: From the Early/Expanded Access Committee - Now available in 10 states (see list below in this post) with additional states [...]

By Malecare|2017-10-19T10:51:07-04:00May 31st, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Enzalutamide (MDV-3100), General Information, MDV3100, Uncategorized|3 Comments

Breaking News- MDV-3100 Starts an Expanded Access Program in the United States

Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutamide (MDV3100) in the United States for men with metastatic prostate cancer previously treated with chemotherapy. Medivation, Inc. and Astellas Pharma Inc. today announced that they have come to an agreement with the U.S. Food and Drug Administration (FDA) which will allow them to proceed [...]

By Malecare|2012-05-30T10:17:46-04:00May 30th, 2012|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), FDA, MDV3100, Uncategorized|0 Comments